MYNZ News and Press, Mainz Biomed B.V.

2024-07-10 08:31:07 ET More on Mainz Biomed B.V. Seeking Alpha’s Quant Rating on Mainz Biomed B.V. Historical earnings data for Mainz Biomed B.V. Financial information for Mainz Biomed B.V. Read the full article on Seeking Alpha For further det...

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clinical analysis of this new configuration demonstrates sens...

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first six months ending June 30, 2024, and provided a cor...

BowFlex Inc. (BFXXQ) is expected to report for Q4 2024 Leafbuyer Technologies Inc (LBUY) is expected to report for Q3 2024 Pacific Booker Minerals Inc (PBMLF) is expected to report for Q1 2025 BZAM Ltd Com (BZAMF) is expected to report for Q1 2024 MJ Holdings Inc (MJNE) is expecte...

Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...

MJ Holdings Inc (MJNE) is expected to report for Q1 2024 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.17 for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Luna Innovations Incorporated (LUNA) is expected to report $-0.01 for Q1 2024 Cano Health...

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently g...

BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, held its annual general meeting (“Annual General Meeting”) on Friday, May 31, 2024 in Amster...

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, ...

Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...